ASH 2012 Highlights
Saturday, January 12, 2013
7:30 am – 4:00 pm
Westin Waltham-Boston Hotel
70 Third Avenue
Waltham, MA
Offered by Dana-Farber/Brigham and Women's Cancer Center, the Leukemia and Lymphoma Society, and Harvard Medical School Department of Continuing Education.
Quicklinks
Course Overview | Agenda | Faculty
Registration Information | Credits | Directions and Parking
Course Overview
The care of patients with hematologic malignancies is evolving rapidly. The growing increase in incidence and mortality, along with complexity of current treatment, heightens the needs of practitioners to keep abreast of the latest developments in treatment. This course is intended to provide attendees with an enhanced understanding of emerging treatments available for blood cancers and blood disorders, and how to apply these new therapies into daily practice. It is designed for hematologists, medical oncologists, internists of recently diagnosed patients, oncology nurses and other interested clinicians.
At this full-day course, an in-depth review of recent developments in the diagnosis and management of hematologic malignancies will be shared, as presented at the 2012 Annual Meeting of the American Society of Hematology (ASH), where cutting-edge therapeutic advances are presented publicly for the first time. Through lecture and case-based presentations, relevant updates on advances in acute leukemia, myelodysplasia, myeloproliferative disorders, lymphoma, multiple myeloma, coagulation disorders, and stem cell transplantation will be discussed.
Learning Objectives
At the conclusion of this course, attendees will be able to: highlight the recent medical advances presented at the 2012 Annual Meeting of the American Society of Hematology (ASH), which will help physicians achieve better patient outcomes; recognize appropriate management and treatment options for hematologic malignancies, and utilize these approaches in routine clinical practice.
ACGME COMPETENCIES: This course has been designed to enhance one or more of the following Accreditation Council of Graduate Medical Education competencies: Patient care, Medical knowledge, Practice-based learning and improvement.
About the Center for Hematologic Oncology at Dana-Farber/Brigham and Women's Cancer Center
We offer advanced, specialized care for patients with all types of hematologic malignancies, including leukemia and similar bone marrow disorders, lymphoma, multiple myeloma, Waldenstrom's macroglobulinemia, and other related blood disorders.
Dana-Farber/Brigham and Women's Cancer Center is at the forefront of stem cell transplantation, performing more than 450 transplants each year. Our team of specialists are national leaders in basic and clinical research designed to bring cutting-edge, innovative therapies to patients with blood cancers. The program is committed to working closely with referring oncologists to jointly devise clinical strategies to improve the care of our patients.
Agenda
7:30 am
Registration and Continental Breakfast
8:00 am
Welcome and Introduction
Robert J. Soiffer, MD
8:15 am
Lymphoma
Ann S. LaCasce MD
9:00 am
Acute Lymphocytic Leukemia (ALL) and Chronic Myelogenous Leukemia (CML)
Daniel J. DeAngelo, MD, PhD
9:30 am
Acute Myeloid Leukemia (AML) and Acute Promyelocytic Leukemia (APL)
Richard M. Stone, MD
10:00 am
Myeloproliferative Neoplasm (MPN) and Myelodysplastic Syndrome (MDS)
David P. Steensma, MD
10:30 am
Break
10:45 am
Coagulation
Jean M. Connors, MD
11:30 am
Multiple Myeloma
Jacob Laubach, MD, MPP
12:15 pm
Lunch
1:15 pm
Chronic Lymphocytic Leukemia (CLL)
Jennifer R. Brown, MD, PhD
2:00 pm
Stem Cell Transplantation
Edwin P. Alyea III, MD
2:45 pm
Case Discussions: MDS, Multiple Myeloma, Follicular Lymphoma
Moderator: Robert J. Soiffer, MD
4:00 pm
Closing Remarks and Meeting Adjourn
Faculty
Robert J. Soiffer, MD, Course Director
Chief, Hematologic Malignancies
Co-Chief, Stem Cell/Bone Marrow Transplantation Program
Dana-Farber/Brigham and Women's Cancer Center;
Professor of Medicine
Harvard Medical School
Edwin P. Alyea III, MD
Associate Director, Stem Cell/Bone Marrow Transplantation Program
Dana-Farber/Brigham and Women's Cancer Center;
Associate Professor of Medicine
Harvard Medical School
Jennifer R. Brown, MD, PhD
Director, Chronic Lymphocytic Leukemia Center
Dana-Farber/Brigham and Women's Cancer Center;
Assistant Professor of Medicine
Harvard Medical School
Jean M. Connors, MD
Medical Director, Anticoagulation Management Service
Dana-Farber/Brigham and Women's Cancer Center;
Assistant Professor of Medicine
Harvard Medical School
Daniel J. DeAngelo, MD, PhD
Medical Oncologist, Hematologic Oncology
Dana-Farber/Brigham and Women's Cancer Center;
Associate Professor of Medicine
Harvard Medical School
Ann S. LaCasce, MD
Director, Dana-Farber/Partners CancerCare Hematology-Medical Oncology Fellowship Program
Dana-Farber/Brigham and Women's Cancer Center;
Assistant Professor of Medicine
Harvard Medical School
Jacob Laubach, MD, MPP
Medical Oncologist, Hematologic Oncology
Dana-Farber/Brigham and Women's Cancer Center;
Instructor in Medicine
Harvard Medical School
David P. Steensma, MD
Medical Oncologist, Hematologic Oncology
Dana-Farber/Brigham and Women's Cancer Center;
Associate Professor of Medicine
Harvard Medical School
Richard M. Stone, MD
Director, Adult Leukemia Program
Dana-Farber/Brigham and Women's Cancer Center;
Professor of Medicine
Harvard Medical School
HMS Disclosure Policy
Harvard Medical School (HMS) adheres to all ACCME Essential Areas, Standards, and Policies. It is HMS's policy that those who have influenced the content of a CME activity (e.g. planners, faculty, authors, reviewers and others) disclose all relevant financial relationships with commercial entities so that HMS may identify and resolve any conflicts of interest prior to the activity. These disclosures will be provided in the activity materials along with disclosure of any commercial support received for the activity. Additionally, faculty members have been instructed to disclose any limitations of data and unlabeled or investigational uses of products during their presentations.
CME Credits
The Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for physicians.
The Harvard Medical School designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Credits
Up to 6.75 hours of Continuing Education Credit will be awarded for this lecture by The Leukemia & Lymphoma Society. Nurses must provide their RN license number in order to receive credit. Provider approved by the California Board of Registered Nursing, Provider number CEP5832.
Registration Information
Registration Fee: $75.00 (non-refundable).
Registration fee includes: continental breakfast, lunch, course materials, and complimentary parking.
To register by mail: Send a completed registration form and check made payable to DF/BWCC to:
ASH 2012 Highlights CME
Dana-Farber Cancer Institute
Attn: Kamira Wooten
450 Brookline Avenue, OS 381
Boston, MA 02215
Registration form must be postmarked no later than December 31, 2012.
If you have food allergies, or if you require accommodations such as an ASL interpreter, materials in alternative format or wheelchair access, please email kwooten@partners.org or call 800-553-3787.
Directions and Parking
This course will be held at the Westin Waltham-Boston Hotel located at 70 Third Avenue in Waltham, MA 02451. Complimentary parking is available on-site at the hotel's garage.
